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Results: The optimal signature contained 28 genes. Therewas a
statistically significant correlation between actual versus pre-
dicted time to recurrence for blind data (rho = 0.975; p < 0.0001).
A prospective Kaplan–Meier plot was generated which showed
no significant difference to the actual Kaplan–Meier plot for this
dataset (p > 0.955).
Discussion: For the first time gene expression signatures have
been identified that predict actual time to event data rather than
placing patients into arbitrary risk groups. Coupled with the abil-
ity to derive prospective Kaplan–Meier plots, this tool has the
potential for assessing prognosis and determining treatment reg-
imens on a case by case basis.
doi:10.1016/j.ejcsup.2010.06.034
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Dynamic contrast-enhanced MRI (DCE-MRI) is a widely used
imaging modality for the management of breast cancer patients.
At present, there is little understanding of how imaging patterns
on DCE-MRI relate to the molecular pathways that drive tumour
growth.
To address this issue, we performed a retrospective study of 65
patients with primary breast cancer, for whom pre-treatment
DCE-MRI scans and formalin fixed paraffin embedded (FFPE) core
biopsies were available. We used pharmacokinetic modelling of
DCE-MRI to quantify the rate constant kep governing contrast
agent washout from the tumour extravascular extracellular
space. By computing the median kep over tumour volume an
overall tumour leakiness score was derived. We extracted RNA
from FFPE cores and measured gene expression using Affymetrix
Human Plus 2.0 arrays. Following normalization and pre-process-
ing, we used permutation tests to determine which genes were
significantly correlated with median kep. Pathway analysis was
performed using GeneCodis with the KEGG database.
Setting the False Discovery Rate to 5% resulted in 1258 genes
that were significantly positively correlated with tumour leaki-
ness including integrins B1 and A6, TGFBR1, HIF1 and 2A, SMAD4,
HES1, JAG1. Interestingly, pathway analysis revealed that the p53
(P < 0.004), Wnt (P < 0.004) and Notch signalling pathways
(P < 0.006), which are known to have important roles in angiogen-
esis, were all significantly associated with tumour leakiness.
These results illustrate how the combination of non-invasive
imaging and gene expression profiling can reveal the molecular
correlates of radiological features and provide insight into the
mechanisms driving tumour growth and angiogenesis.
doi:10.1016/j.ejcsup.2010.06.035
O-35 SERPINB3, A BIOMARKER OF TAXANE BENEFIT IN BREAST
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Background: Lysosomal cathepsin proteases function in a pro-
grammed cell death (LPCD) pathway. Although there is evidence
for the importance of this pathway in cancer cell survival, it has
not been exploited in anti-cancer therapeutics. Hsp70 and ser-
pinB3 can block this pathway and promote cell survival. Further-
more, serpinB3 is associated with lack of response to
chemotherapy. Cathepsin mediated cell death is observed in
response to anthracyclines or taxanes, which are widely utilised
in breast cancer treatment.
Methods: We evaluated serpinB3 and Hsp70 by immunohisto-
chemistry in 255 surgically resected breast tumours from patients
treated with either CVAP or CVAP and docetaxel prior to poten-
tially curative resection. The study was performed with the
approval of the regional research ethics committee.
Results: SerpinB3 and Hsp70 were significantly correlated with
poor pathological response (P = 0.014 and P < 0.0001, respectively).
SerpinB3 positivity is a poor prognostic factor (P = 0.029; mean
survival 88.8 vs. 100.4 months) and this is independent in multi-
variate analysis (P = 0.023). Patients with serpinB3 positive
tumours have poor survival if treated with anthracycline
(P = 0.026) but not if they are also given a taxane (P = 0.786). Fur-
thermore, only patients with serpinB3 positive tumours benefit
from taxane treatment (P = 0.008).
Conclusions: SerpinB3 and Hsp70 are predictive biomarkers,
potentially blocking breast tumour response to chemotherapy
by preventing LPCD. SerpinB3 is prognostic and may prevent
anthracycline-, but not taxane-, mediated cytotoxicity in breast
tumours. Patients with serpinB3 negative tumours have a good
prognosis when treated with anthracycline-based therapy alone.
In contrast, patients with serpinB3 positive tumours benefit sig-
nificantly from the addition of docetaxel.
doi:10.1016/j.ejcsup.2010.06.036
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We have shown that insulin receptor substrate 1 (IRS-1) can
associate with epidermal growth factor receptor (EGFR), with acti-
vation of EGFR promoting recruitment and phosphorylation of
IRS-1 in an oestrogen receptor (ER)-positive tamoxifen resistant
breast cancer (BC) cell line. In this study, we examined recruit-
ment of IRS-1 by another erbB receptor family member, erbB3 in
three ER-positive BC cell lines. Our studies revealed an interaction
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between erbB3 and IRS-1 in MCF-7, T47-D and BT-474 cells with
HRGb1 treatment enhancing this recruitment and promoting
IRS-1 phosphorylation at tyrosine (Y) 612, a specific PI3-K binding
site. In addition, siRNA knockdown of IRS-1 greatly impaired
HRGb1 signalling via PI3-K/AKT in these cells. This novel interac-
tion may have clinical relevance as immunohistochemical analy-
sis of ER-positive BC patient samples revealed IRS-1 Y612
expression positively correlated with total erbB3, p-AKT and
Ki67 expression. Importantly, we found that association of IRS-1
by erbB3 impaired IRS-1 recruitment by IGF-IR in both MCF-7
and T47D cells, whilst blockade of IGF-1R enhanced erbB3/IRS-1
interaction and sensitised both cell lines to HRGb1. Consequently,
knockdown of IRS-1 reduced HRGb1 action and enhanced the
effects of IGF-IR inhibition in these cells. In conclusion, these
and previous findings suggest that IRS-1 can be recruited to IGF-
1R, EGFR and erbB3 in ER-positive BC cells and this may provide
an adaptive resistance mechanism when these receptors are tar-
geted individually. Consequently co-targeting of IGF-IR and erbB
receptors/IRS-1 may prove to be a more effective strategy for
the treatment of ER-positive BC.
doi:10.1016/j.ejcsup.2010.06.037
O-37 SOX11 AND PSMD3 EXPRESSION IN HER2 POSITIVE
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Human Epidermal Receptor 2 (HER2)+ have attracted attention
as a poor prognostic class of breast cancer. However, HER2+
tumours appear to encompass biologically and clinically hetero-
geneous tumours.
In order to refine HER2+ breast cancer, we analysed over 48,000
gene transcripts in 132 invasive breast carcinomas using Artificial
Neural Network analysis and identified high expression of two
novel genes (SOX11, PSMD3) significantly associated HER2+ posi-
tivity. Using a large invasive breast carcinoma cohort (n = 1,298),
prepared as tissue microarrays, we assessed these targets using
immunohistochemistry and investigated associations with clini-
copathological variables, patients’ outcome and ability to refine
HER2+ classification.
PSMD3 nuclear expression was observed in 219/942 (23%) of
tumours and was significantly correlated to HER2 positivity
(p = 0.004), tubule formation (p = 0.047) and NPI (p = 0.007). PSMD3
expression conferred a strong trend towards a longer breast can-
cer specific survival in the whole series (p = 0.065). SOX11 nuclei
staining was observed in 96/869 (3.8%) tumours and was signifi-
cantly associated with ER (p = 0.006) and PSMD3 nuclear
(p < 0.001) positivity and ck14 negativity (p = 0.018) but not HER2.
SOX11 expression did not predict patient clinical outcome in
either the whole series or HER2+ tumours only.
This study confirms the biological and clinical heterogeneity
of HER2+ tumours and the difficulties in translating global gene
expression data into routine practice using immunohistochemis-
try. We have identified two novel genes associated with HER2+
tumours and further studies analysing the role of PSMD3 expres-
sion in this important subtype is warranted.
doi:10.1016/j.ejcsup.2010.06.038
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Introduction: Recent seminal findings from our institution indi-
cate that systemic miR-195 and Let-7a levels have potential as
non-invasive breast cancer biomarkers. We aimed to validate
these findings in an expanded cohort and to identify further miR-
NAs which augment the sensitivity and specificity of circulating
miRNAs as diagnostic and prognostic markers for breast cancer.
Methods: The expression levels of nine miRNAs were evaluated
in an expanded cohort of 265 breast cancer patients, 80 non-
breast malignancies (colon, renal, prostate and melanoma) and
63 age-matched disease-free controls using RQ-PCR. Eleven addi-
tional miRNAs were evaluated as potential miRNA endogenous
controls. Advanced QBase plus software and SPSS were used for
biostatistical analysis of the data and correlation with clinico-
pathological variables.
Results: This study confirmed significantly deranged expres-
sion levels of systemic miR-195 and Let-7a and two additional
miRNAs in breast cancer patients compared to disease-free con-
trols. Elevated miR-195 was identified to be breast cancer-specific,
with a sensitivity of 88% and a specificity of 91%. A combination
of three circulating miRNAs, including miR-195 and Let-7a,
increased the discriminatory power of this test for breast cancer
to 94%. Of the eleven candidate miRNAs selected for normalisa-
tion, two were identified to be stably expressed in a subset of
the original cohort and thus are ideal endogenous controls for
blood based miRNA studies.
Conclusion: This study highlights the presence and dysregula-
tion of cancer-specific miRNAs in the circulation of breast cancer
patients and illustrates the potential for this systemic miRNA sig-
nature to aid in the diagnosis and prognostication of this disease.
doi:10.1016/j.ejcsup.2010.06.039
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MULTICENTRE AUDIT
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